Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib

Medicine (United States)

Volumn 94, Issue 22, 2015, Pages e887-

  Aydiner, Adnan ^a   Ciftci, Rumeysa ^a   Sen, Fatma ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERLOTINIB; FOSINOPRIL; HORMONE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; RAMIPRIL; RENIN ANGIOTENSIN SYSTEM BLOCKER; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNCLASSIFIED DRUG; VALSARTAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SMOKING; SYSTEMIC THERAPY; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84940986495     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000887     Document Type: Article

References (26)

1. Jemal A, iegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2007;57:43-66.
2. Li P, Kondo T, Numaguchi Y, et al. Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Hypertension. 2008;51:252-258.
3. Toma B, Dendorfer A, Jan Danser AH. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int J Biochem Cell Biol. 2003;35:792-801.
4. Gallagher PE, Cook K, Soto-Pantoja D, Menon J, Tallant EA. Angiotensin peptides and lung cancer. Curr Cancer Drug Targets. 2011;11:394-404.
5. Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res. 2005;11:2686-2694.
6. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16:293-299.
7. Rodrigues-Ferreira S, Abdelkarim M, Dillenburg-Pilla P, et al. Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One. 2012;7:.
8. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihypertensives as novel antineoplastics:angiotensin-i-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg. 2007;204:996-1005.
9. Dolley-Hitze T, Jouan F, Martin B, et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer. 2010;103:1698-1705.
10. Feng Y, Wan H, Liu J, et al. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep. 2010;23:941-948.
11. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Comm. 2002;294:441-447.
12. Romer FK. Angiotensin-converting enzyme and its association with outcome in lung cancer. Br J Cancer. 1981;43:135-142.
13. Eguchi S, Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept. 2000;91: 13-20.
14. Qian YR, Guo Y, Wan HY, et al. Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. Oncol Rep. 2013;29:2408-2414.
15. Chauhan VP, Martin JD, Liu H, et al. Angiotensin inhibition enhances drug deliver and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.
16. Wilop S, von Hobe S, Crysandt M, et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135:1429-1435.
17. Kim ST, Park KH, Oh SC, et al. How does nhibition of the reninangiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology. 2012;83:354-360.
18. Nakai Y, Isayama H, Ijichi H, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 2010;103:1644-1648.
19. Ni L, Feng Y, Wan H, et al. Angiotensin(1-7) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signalling pathways. Oncol Rep. 2012;27:783-790.
20. Batra VK, Gopaladrishnan V, McNeill JR, et al. Angiotensin II elevates cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors. Cancer Lett. 1994;76:19-24.
21. Uhal BD, Gidea C, Bargout R, et al. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol. 1998;275:L1013-L1017.
22. Tamura M, Yan H, Zegarra-Moro O, et al. Specific single chain variable fragment (ScFv) antibodies to angiotensin II AT(2) receptor: evaluation of the angiotensin II receptor expression in normal and tumor-bearing mouse lung. J Mol Histol. 2008;39:351-358.
23. Papp M, Li X, Zhuang J, Wang R, Uhal BD. Angiotensin receptor subtype AT1 mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol. 2002;282:L713-L718.
24. Pickel L, Matsuzuka T, Doi C, et al. Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol Ther. 2010;9:277-285.
25. Shipp MA, Tarr GE, Chen CY, et al. CD10/Neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A. 1991;88:10662-10666.
26. Ohnuma Y, Toda M, Fujita M, et al. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother. 2009;63:136-145.